AVIVAGEN INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.005 CAD | -.--% |
|
-.--% | -.--% |
| 2023 | Avivagen Inc. Announces New 500 Kg Order for OxC-beta | CI |
| 2023 | Avivagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023 | CI |
Valuation
| Fiscal Period: October | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 29.16 | 21.48 | 15.71 | 17.33 | 22.5 | 10.42 |
| Enterprise Value (EV) 1 | 28.74 | 21.53 | 19.21 | 22.8 | 27.9 | 16.22 |
| P/E ratio | -5.75 x | -4.38 x | -3.2 x | -3.52 x | -3.24 x | -1.47 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 114 x | 20 x | 16.1 x | 14.7 x | 17.4 x | 11.1 x |
| EV / Revenue | 112 x | 20.1 x | 19.7 x | 19.4 x | 21.5 x | 17.3 x |
| EV / EBITDA | -6.46 x | -5.19 x | -4.94 x | -6.75 x | -6.86 x | -3.33 x |
| EV / FCF | -10.3 x | -8.32 x | -7.05 x | -8.43 x | -6.98 x | -6.59 x |
| FCF Yield | -9.67% | -12% | -14.2% | -11.9% | -14.3% | -15.2% |
| Price to Book | 173 x | 229 x | -4.82 x | -3.64 x | -5.69 x | -1.74 x |
| Nbr of stocks (in thousands) | 29,161 | 33,565 | 34,907 | 41,766 | 56,959 | 77,187 |
| Reference price 2 | 1.000 | 0.6400 | 0.4500 | 0.4150 | 0.3950 | 0.1350 |
| Announcement Date | 12/20/17 | 1/30/19 | 12/19/19 | 12/15/20 | 1/19/22 | 2/21/23 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: October | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.2557 | 1.073 | 0.9775 | 1.178 | 1.296 | 0.9392 |
| EBITDA 1 | -4.447 | -4.146 | -3.888 | -3.38 | -4.067 | -4.87 |
| EBIT 1 | -4.459 | -4.149 | -3.893 | -3.387 | -4.108 | -4.898 |
| Operating Margin | -1,744.17% | -386.82% | -398.27% | -287.56% | -316.95% | -521.5% |
| Earnings before Tax (EBT) 1 | -5.046 | -4.834 | -4.836 | -4.751 | -6.394 | -6.066 |
| Net income 1 | -5.046 | -4.834 | -4.836 | -4.751 | -6.394 | -6.066 |
| Net margin | -1,973.58% | -450.7% | -494.8% | -403.38% | -493.38% | -645.91% |
| EPS 2 | -0.1738 | -0.1462 | -0.1407 | -0.1179 | -0.1219 | -0.0919 |
| Free Cash Flow 1 | -2.779 | -2.586 | -2.726 | -2.704 | -3.996 | -2.46 |
| FCF margin | -1,086.91% | -241.09% | -278.91% | -229.57% | -308.35% | -261.98% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 12/20/17 | 1/30/19 | 12/19/19 | 12/15/20 | 1/19/22 | 2/21/23 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: October | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.1596 | 0.5059 | 0.3685 | 0.2712 | 0.0884 | 0.0486 | 0.531 |
| EBITDA | -1.142 | -1.055 | -0.9653 | -1.074 | -1.294 | -1.454 | - |
| EBIT 1 | -1.176 | -1.084 | -0.9938 | -1.1 | -1.314 | -1.474 | -1.009 |
| Operating Margin | -736.95% | -214.2% | -269.68% | -405.69% | -1,485.95% | -3,033.26% | -190.04% |
| Earnings before Tax (EBT) 1 | -2.198 | -1.504 | -1.427 | -1.553 | -1.304 | -1.901 | -1.308 |
| Net income 1 | -2.198 | -1.504 | -1.427 | -1.553 | -1.304 | -1.901 | -1.308 |
| Net margin | -1,376.89% | -297.23% | -387.12% | -572.67% | -1,474.08% | -3,911.64% | -246.38% |
| EPS 2 | -0.0400 | -0.0300 | -0.0200 | -0.0300 | -0.0200 | -0.0300 | -0.0200 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 6/2/21 | 9/28/21 | 1/19/22 | 3/30/22 | 6/15/22 | 9/16/22 | 2/21/23 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: October | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 0.05 | 3.5 | 5.47 | 5.4 | 5.8 |
| Net Cash position 1 | 0.42 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.011 x | -0.9006 x | -1.617 x | -1.327 x | -1.19 x |
| Free Cash Flow 1 | -2.78 | -2.59 | -2.73 | -2.7 | -4 | -2.46 |
| ROE (net income / shareholders' equity) | -265% | -3,682% | 306% | 118% | 147% | 122% |
| ROA (Net income/ Total Assets) | -79.1% | -105% | -97.4% | -104% | -90.8% | -126% |
| Assets 1 | 6.378 | 4.622 | 4.966 | 4.561 | 7.041 | 4.799 |
| Book Value Per Share 2 | 0.0100 | 0 | -0.0900 | -0.1100 | -0.0700 | -0.0800 |
| Cash Flow per Share 2 | 0.0500 | 0.0700 | 0.0300 | 0.0200 | 0.0200 | 0 |
| Capex | - | 0.07 | 0.11 | 0.04 | 0.01 | - |
| Capex / Sales | - | 6.48% | 11.17% | 3.76% | 0.67% | - |
| Announcement Date | 12/20/17 | 1/30/19 | 12/19/19 | 12/15/20 | 1/19/22 | 2/21/23 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 284K | |
| +11.33% | 11.43B | |
| -0.75% | 5.77B | |
| -4.08% | 4.87B | |
| -5.10% | 4.14B | |
| -23.66% | 2.58B | |
| -5.06% | 1.75B | |
| -24.53% | 1.11B | |
| -18.46% | 865M | |
| +24.67% | 855M |
- Stock Market
- Equities
- VIV Stock
- Financials Avivagen Inc.
